THZ1 - Covalent CDK7 Inhibitor. CAS# 1604810-83-4 284 Evaluation of the effects of

Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects

110 nM and 70 nM

is a potent and selective antagonist for the prostaglandin E2 receptor subtype EP2

InChiKey: LIDOPKHSVQTSJY-VMEIHUARSA-N

513(7516):124-7

THZ1 - Covalent CDK7 Inhibitor. CAS# 1604810-83-4 284 Evaluation of the effects ofTHZ1, CAS No. 1604810 83 4, is a novel potent, selective and cell permeable irreversible CDK7 inhibitor with an IC50 ~3. 2 nM. THZ1 has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. Cancer cell line profiling indicates that a subset of cancer cell lines, including human T cell acute lymphoblastic leukaemia (T ALL), have